Chemical biologist passionate about post-translational modifications (PTMs) and a keen interest in drug development. Professor at OHSU leading a team dedicated to unraveling the mysteries of PARPs and ADP-ribosylation.
They demonstrate that a common PARP1 variant (V762) shifts talazoparib from a non-retentive (Type II) to an allosteric, pro-retention (Type I) mode, thereby boosting chromatin trapping and cancer cell killing. The finding makes a strong case for genotype-guided dosing in HRD cancer therapy.
November 13, 2025 at 6:42 PM
They demonstrate that a common PARP1 variant (V762) shifts talazoparib from a non-retentive (Type II) to an allosteric, pro-retention (Type I) mode, thereby boosting chromatin trapping and cancer cell killing. The finding makes a strong case for genotype-guided dosing in HRD cancer therapy.